2016 New Antibacterial Discovery and Development Gordon Research Conference and Gordon Research Seminar
2016 New Antibacterial Discovery and Development Gordon Research Conference and Gordon Research Seminar
批准号:
9023674
负责人:
Jennifer Alyson Leeds
金额:
$0.7万
依托单位国家:
美国
项目类别:
财政年份:
2016
资助国家:
美国
项目状态:
已结题
起止时间:
2016-02-15 至 2017-01-31
关键词:
AcademiaAddressAdjuvantAnti-Bacterial AgentsAntibiotic ResistanceAntibioticsAreaBasic ScienceBiotechnologyChargeChemicalsClinicClinicalClinical DataClinical PathwaysClinical TrialsClinical Trials DesignCollaborationsCommunitiesCommunity NetworksCompanionsCritical ThinkingCritiquesDataData AnalysesDevelopmentDiagnosisDiagnosticDrug IndustryDrug resistanceEducational workshopEnvironmentEuropeExperimental DesignsFosteringFoundationsGenerationsGoalsGovernmentGovernment AgenciesHumanIndustryInfectionLeadershipLearningMedicineMicrobial PhysiologyOrganismOrganizational ChangeOutcomeParticipantPatientsPharmaceutical ChemistryPharmaceutical PreparationsPharmacologyPreclinical TestingProgram DevelopmentResearchResearch PersonnelRisk-TakingSafetyScientistSiteTalentsTimeTranslational ResearchValidationbasecareerdesigndrug developmentdrug discoveryexperienceinnovationinterestmeetingsnew technologynext generationnovelnovel strategiespostersprogramspublic health relevanceresearch facilitysuccesssupport networksymposium
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by the applicant): The 2016 Gordon Research Conference on New Antibacterial Discovery and Development and the companion Gordon Research Seminar will bring highly experienced leaders in antibacterial drug discovery and development together with young investigators and those new to the field of antibiotics research in order to enable the next generation of safe and effective drugs. Discussion leaders and speakers are chosen from academia, industry, and government agencies to emphasize the breadth of talent and leadership necessary to drive innovation around target discovery and validation, hit identification
and chemical optimization, and clinical trial design and execution. Previous meetings have defined the problem of antibiotic resistance, the challenges in antibiotic discovery and development faced over the past two decades, and the need for new pathways for clinical development. Those meetings have successfully created a community of idea generation and collaboration in what is otherwise a highly competitive scientific arena. This meeting will build o those foundations by exploring 1) novel strategies for achieving potent and safe antibacterial drugs against the most difficult-to- treat organisms, 2) new approaches for diagnosing infections with the goal of broadening the opportunities for clinical development as well as guiding the appropriate use of precious new antibacterial drugs in the clinic, and 3) learnings from recent clinical programs with new and established targets which may be translatable to the next generation of antibacterial drugs. Many strategic and organizational changes have taken place in the biotech and pharmaceutical industry over the last few years as well as a shift in emphasis at academic and government research facilities from early basic science to translational research. Because of the ever-changing environment, there has never been a more critical time for fostering a community of intellectuals dedicated to innovation and calculated risk-taking. This
GRC/GRS will enable critical thinking, robust discussions around data gathering and interpretation, and learning from each other's challenges and successes. Most importantly the GRC/GRS meeting will provide a community and support network for scientists who have dedicated their careers to one of the most difficult and essential areas of human medicine.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金